Recent studies have attached importance to the dysregulated AR expression in prostate cancer and its underlying mechanisms because these represent the most therapeutically relevant targets in this disease.2 Although numerous researches have focused on the regulation of AR synthesis in prostate cancer, the regulation of AR post-translational modification and degradation has been historically underappreciated. The gene discussed is AR; the disease is prostate carcinoma.